Flow Chart for the Therapy of Newly Diagnosed Acute Myeloid Leukemia (AML) - Flowchart
Flow Chart for the Therapy of Newly Diagnosed Acute Myeloid Leukemia (AML) - Flowchart
«Flowchart»

Diagnosis AML

Diagnosis AML

Diagnosis AML

Diagnosis AML

Salvage treatment

Salvage treatment

Salvage treatment

Previously untreated

Previously untreated

Previously untreated Previously untreated

Refractory or relapsed

Refractory or relapsed

Refractory or relapsed Refractory or relapsed

CBF AML: t(8;21) or inv(16) or t(16;16)

CBF AML: t(8;21) or inv(16) or t(16;16)

CBF AML

Low-risk normal cytogenetics (CEBPA double mutations or NPM1 mutations without FLT3-ITD)

Low-risk normal cytogenetics (CEBPA double mutations or NPM1 mutations without FLT3-ITD)

CEBPA NPM1 FLT3 Low-risk normal cytogenetics

High-risk normal cytogenetics (FLT3-ITD and/or NPM1 wild type) and High risk abnormal cytogenetics

High-risk normal cytogenetics (FLT3-ITD and/or NPM1 wild type) and High risk abnormal cytogenetics

FLT3 NPM1 High-risk normal cytogenetics

If CR: Investigational molecular targeted therapy

If CR: Investigational molecular targeted therapy

If CR: Investigational molecular targeted therapy

If CR:

If CR, consolidation therapy: High-dose cytarabine

If CR, consolidation therapy: High-dose cytarabine

If CR, consolidation therapy: High-dose cytarabine

If CR, consolidation therapy:

Either option acceptable

Either option acceptable

Either option acceptable

Induction therapy: Daunorubicin+cytarabine-based regimen

Induction therapy: Daunorubicin+cytarabine-based regimen

Induction therapy: Induction therapy

Investigational molecular targeted therapy

Investigational molecular targeted therapy

Investigational molecular targeted therapy

Refractory or relapsed

Refractory or relapsed

Refractory or relapsed

If CR, consolidation therapy: High-dose cytarabine or autologous HSCT

If CR, consolidation therapy: High-dose cytarabine or autologous HSCT

If CR, consolidation therapy: High-dose cytarabine or autologous HSCT

If CR, consolidation therapy:

If CR: Investigational molecular targeted therapy

If CR: Investigational molecular targeted therapy

If CR: Investigational molecular targeted therapy

If CR:

Either option acceptable

Either option acceptable

Either option acceptable

Induction therapy: Daunorubicin+cytarabine-based regimen

Induction therapy: Daunorubicin+cytarabine-based regimen

Induction therapy: Induction therapy

Investigational molecular targeted therapy

Investigational molecular targeted therapy

Investigational molecular targeted therapy

If CR, consolidation therapy: Allogeneic HSCT

If CR, consolidation therapy: Allogeneic HSCT

If CR, consolidation therapy: Allogeneic HSCT

If CR, consolidation therapy:

If CR: investigational therapy

If CR: investigational therapy

If CR: investigational therapy

If CR:

Either option acceptable

Either option acceptable

Either option acceptable

Induction therapy: Daunorubicin+cytarabine-based regimen

Induction therapy: Daunorubicin+cytarabine-based regimen

Induction therapy: Induction therapy

Investigational therapy

Investigational therapy

Investigational therapy

End

End

End

Patient candidate for allogeneic HSCT and has suitable donor

Patient candidate for allogeneic HSCT and has suitable donor

Patient candidate for allogeneic HSCT and has suitable donor

Yes: Allogeneic HSCT

Yes: Allogeneic HSCT

Yes: Yes

No: Investigational therapy

No: Investigational therapy

No: No